ANTHIM® (oblitoxaximab) is a Medical Countermeasure to Mitigate the Effect of Anthrax Exposure

Elusys has been awarded over $400 million in procurement and development contracts by the Biomedical Advanced Research and Development Authority (BARDA), the National Institute of Allergy and Infectious Disease (NIAID) and the Department of Defense (DoD). Working closely with these agencies, Elusys has been able to advance ANTHIM® to the commercial stage providing a therapeutic for inclusion in the Strategic National Stockpile to strengthen US biosecurity against a potential anthrax attack. Elusys was also contracted as of 2022 to deliver ANTHIM® to the Public Health Agency of Canada. Oblitoxaximab was first licensed for commercial use by the FDA in 2016 and by the European Union and Canada in 2020 and the Great Britain in 2021. 

Obiltoxaximab is a monoclonal anthrax antitoxin licensed as ANTHIM® in the United States and Canada and as NYXTHRACIS® in the Great Britain and the European Union.  Details including Indications and Usage and Important Safety Information can be found by visiting the website below.


Anthim Logo

ANTHIM® (obiltoxaximab)

ANTHIM® (obiltoxaximab)

descriptionUS Prescribing Information

descriptionCanadian Monograph (English)

descriptionCanadian Monograph (French)

NYXTHRACIS® (obiltoxaximab)

descriptionEU Summary of Product Characteristics (SmPC) (EN)

descriptionGB Summary of Product Characteristics (SmPC) (EN)

*SFL Pharmaceuticals Deutschland GmbH is the EU Marketing Authorization Holder